7 ± 7.9 years. Demographic data for the 14 remaining patients (seven in diversity group 1, four in group 2, three in group 3) are shown in Table 1. This cohort was predominantly white (86 %) and had a mean (±SD) age of 68.0 ± 11.3 years and a mean disease duration of 5.9 ± 5.3 years. Seven patients were recruited at each of the two clinical sites. In total, Liproxstatin-1 nmr 14 fractures had been sustained by ten of the 14 patients. Five of these fractures affected the spine. Remaining fractures were distributed among hip (n = 2), wrist (n = 1), shoulder (n = 1), ribs (n = 2), femur (n = 1), and foot/toe (n = 2).

It proved impossible to recruit patients who were free of comorbid conditions that might be associated with fatigue, poor sleep, pain, or limited mobility, and comorbid conditions affecting these patients included Parkinson’s disease, polymyalgia rheumatica, breast cancer, hyperlipidemia, osteoarthritis, rheumatoid arthritis, and diabetes. Table 1 Participant characteristics,

phase 2 (qualitative research) Characteristic First stage (n = 14) Second stage (n = 18) Age (years; mean ± SD) 68.0 ± 11.3 70.0 ± 9.2 Ethnicity (n [%])      White 12 (85.7) 15 (83.3)  Black/African American 1 (7.1) 0  Asian 1 (7.1) 0  Hispanic/Latino 0 1 (5.6)  Middle Eastern 0 1 (5.6)  Mixed 0 1 (5.6) Main activity (n [%])      Employed full time 2 (14.3) 4 (22.2)  Employed part time 0 2 (11.1)  Self-employed 1 (7.1) 0  Looking after home see more 4 (28.6) 2 (11.1)  Retired 5 (35.7) 8 (44.4)  Disabled 2 (14.3) 2 (11.1) Disease duration (years; mean ± SD) 5.9 ± 5.3 6.0 ± 4.1 Diversity group (n [%])      Group 1 7 (50.0) 8 (44.4)  Group 2 4 (28.6) 5 (27.8)  Group 3 3 (21.4) 5 (27.8) T-score      Total hip (median [range]) −2.2 (−3.3 to −0.7) −2.3 (−3.1 to −1.1)  Femoral neck (median [range]) −2.5 (−3.8 to −0.7) −2.6 (−3.3 to −1.0)  Lumbar spine (median [range]) −2.2 (−3.7 to −0.4) −2.1

(−3.9 to −0.6) Fracture site (number of fractures)      Hip 2 5  Spine 5 3  Wrist 1 1  Ankle 0 1  Distal forearm 0 1  Shoulder 1 0  Humerus 0 2  Ribs 2 1  Pelvis 0 1  Femur 1 0  Foot/toe 2 1 SD standard deviation First stage: concept Selleckchem MK-0457 elicitation In this part of the interview, participants were asked about: Enzalutamide cost (1) impacts osteoporosis had on their lives; (2) activities they were able/unable to do or avoided; and (3) any symptoms of which they were aware. The interviews therefore had a broader focus than the content of the instrument administered at that stage. We report here only the findings of relevance to the content of the final version of OPAQ-PF. Relevant concept elicitation data from the first stage interviews are presented in conjunction with concept elicitation data from the second stage interviews in Table 2, and described in the section titled “Second stage: concept elicitation”. In the first stage of phase 2, no new codes were added after the 12th concept elicitation interview, demonstrating that data saturation was achieved.